Which oral glucose‑lowering agents can be used in patients with chronic kidney disease (CKD), and how should they be dosed according to estimated glomerular filtration rate (eGFR)?

Oral Glycemic Medications for Patients with CKD

First-Line Therapy: Metformin and SGLT2 Inhibitors

All patients with type 2 diabetes and CKD should be treated with metformin (when eGFR ≥30 mL/min/1.73 m²) and an SGLT2 inhibitor (when eGFR ≥20 mL/min/1.73 m²), as these provide kidney and cardiovascular protection independent of glucose-lowering effects. 1, 2

Metformin Dosing by eGFR

• eGFR ≥60 mL/min/1.73 m²: Start 500-850 mg once daily, titrate upward by 500 mg every 7 days to maximum dose (typically 2000 mg/day) 1
• eGFR 45-59 mL/min/1.73 m²: Continue same dose; consider dose reduction in patients with acute illness, volume depletion, or multiple comorbidities 1
• eGFR 30-44 mL/min/1.73 m²: Reduce dose to 1000 mg daily maximum 1, 2
• eGFR <30 mL/min/1.73 m²: Discontinue metformin due to lactic acidosis risk 1, 2

Monitor eGFR at least every 3-6 months when eGFR <60 mL/min/1.73 m², and check vitamin B12 levels in patients on metformin >4 years. 1, 3

SGLT2 Inhibitor Use in CKD

• Initiate SGLT2 inhibitor when eGFR ≥20 mL/min/1.73 m² and continue until dialysis or transplantation, regardless of glycemic control 1, 2
• The kidney and cardiovascular protective benefits persist even as eGFR declines, despite reduced glucose-lowering efficacy 3, 4
• Empagliflozin should be reduced from 25 mg to 10 mg daily when eGFR approaches 45 mL/min/1.73 m², as efficacy and safety diminish below this threshold 3, 4

---

Second-Line Therapy: GLP-1 Receptor Agonists

When glycemic targets are not met with metformin and SGLT2 inhibitor, add a long-acting GLP-1 receptor agonist, as this class reduces major adverse cardiovascular events and slows eGFR decline. 1, 3

GLP-1 RA Dosing in CKD

• Dulaglutide: 0.75-1.5 mg once weekly; no dose adjustment needed; use when eGFR >15 mL/min/1.73 m² 1
• Liraglutide: 1.2-1.8 mg once daily; no dose adjustment needed; limited data in severe CKD 1
• Semaglutide: No dose adjustment required; cardiovascular benefits proven 1
• Exenatide extended-release: Use only when eGFR >45 mL/min/1.73 m² 1

Start with the lowest dose and titrate slowly to minimize gastrointestinal side effects (nausea, vomiting, diarrhea). 1 Prioritize agents with documented cardiovascular benefits (dulaglutide, liraglutide, semaglutide). 1

---

Third-Line Therapy: DPP-4 Inhibitors

When GLP-1 receptor agonists are declined or not tolerated, DPP-4 inhibitors are the next-best evidence-based option, as they carry minimal hypoglycemia risk and are safe in older adults. 3

DPP-4 Inhibitor Dosing by eGFR

• Linagliptin: 5 mg once daily; no dose adjustment required at any eGFR level—this is the preferred DPP-4 inhibitor in CKD 3, 5
• Sitagliptin:
  • eGFR ≥50 mL/min/1.73 m²: 100 mg once daily
  • eGFR 30-49 mL/min/1.73 m²: 50 mg once daily 3
  • eGFR <30 mL/min/1.73 m²: 25 mg once daily 5
• Saxagliptin:
  • eGFR ≥50 mL/min/1.73 m²: 5 mg once daily
  • eGFR <50 mL/min/1.73 m²: 2.5 mg once daily 3

DPP-4 inhibitors have minimal hypoglycemia risk when used without insulin or sulfonylureas, making them particularly safe for older adults with CKD. 3

---

Fourth-Line Options: Use with Extreme Caution

Sulfonylureas (Generally Avoid)

Sulfonylureas should be avoided in older adults with CKD due to substantially increased hypoglycemia risk from drug accumulation. 3, 5 If absolutely necessary:

• Glipizide: 2.5 mg once daily maximum; shortest-acting sulfonylurea with hepatic metabolism 3
• Glyburide: Contraindicated in CKD due to active metabolites that accumulate 5, 6
• Glimepiride: Requires dose reduction; high hypoglycemia risk 5

Thiazolidinediones

• Pioglitazone: No renal dose adjustment required, but avoid in patients at risk for heart failure due to fluid retention 3, 7

Alpha-Glucosidase Inhibitors

• Acarbose/Miglitol: No dose adjustment needed, minimal hypoglycemia risk, but avoid in advanced CKD (eGFR <30 mL/min/1.73 m²) due to accumulation of metabolites 1, 6

---

Critical Safety Monitoring

Renal Function Monitoring

• Check eGFR every 3-6 months when eGFR <60 mL/min/1.73 m² 1, 2
• Temporarily discontinue metformin during acute illness causing volume depletion (sepsis, severe diarrhea, vomiting) or hospitalization with acute kidney injury risk 3

Hypoglycemia Prevention

• Avoid sulfonylureas as add-on therapy in CKD; use DPP-4 inhibitors or GLP-1 RAs instead 3
• Educate patients on hypoglycemia symptoms, which may be blunted in CKD 8

---

Common Pitfalls to Avoid

1. Do not continue metformin when eGFR falls below 30 mL/min/1.73 m²—lactic acidosis risk increases substantially 1, 2

2. Do not reduce metformin dose prematurely at eGFR 50 mL/min/1.73 m²—dose reduction is only required when eGFR 30-44 mL/min/1.73 m² 3

3. Do not discontinue SGLT2 inhibitors when eGFR declines—continue until dialysis or transplantation for kidney and cardiovascular protection 1, 2

4. Do not add sulfonylureas as the next agent in older adults with CKD—DPP-4 inhibitors offer superior safety 3

5. Do not use glyburide in any patient with CKD—active metabolites accumulate and cause prolonged hypoglycemia 5, 6

6. Do not forget to monitor vitamin B12 in patients on metformin >4 years—approximately 7% develop deficiency 3